Drug intelligence / Profile preview

beta-human chorionic gonadotropin

Development stage: Unknown
Lead developer: Ferring Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular, Subcutaneous

Overview

Beta-human chorionic gonadotropin (beta-hCG) is the beta subunit of human chorionic gonadotropin (hCG), a hormone primarily produced by the placenta during pregnancy. Its presence and levels in blood or urine are crucial for diagnosing and monitoring various pregnancy-related conditions, such as ectopic pregnancy, molar pregnancy, and fetal growth restriction. It also serves as a tumor marker for certain cancers, including testicular cancer and gestational trophoblastic disease.

Brand names: NovarelOvidrelPregnylChorexProfasi
Other names: beta-HCGβ-hCG

Targets

TSHR (Thyroid-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)

Beyond the preview

Go deeper on beta-human chorionic gonadotropin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-human chorionic gonadotropin.

Explore the full profile